Table 4 shows the characteristics of ET patients who were JAK2V617F mutation‐positive (JAK2‐ET; n = 34; 64.2%) and CALR mutation‐positive (CALR‐ET; n = 11; 20.8%) groups. This evidence concerns the gene JAK2 and essential thrombocythemia.